Dr. Fedyanin on Future Treatment Landscape of CRC

Mikhail Fedyanin, MD, PhD
Published: Monday, Dec 19, 2016



Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).

There will hopefully be more novel agents approved in the CRC space, Fedyanin explains, such as combination regimens of MEK inhibitors and PD-1 inhibitors. Additionally, he predicts and anticipates more research dedicated to treatments for patients with CRC who harbor KRAS mutations. Currently, there are a lack of effective agents able to target this patient population. 
SELECTED
LANGUAGE


Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).

There will hopefully be more novel agents approved in the CRC space, Fedyanin explains, such as combination regimens of MEK inhibitors and PD-1 inhibitors. Additionally, he predicts and anticipates more research dedicated to treatments for patients with CRC who harbor KRAS mutations. Currently, there are a lack of effective agents able to target this patient population. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x